ATAC's Drug Development Committee (DDC) works with government, academia and the pharmaceutical industry to provide a community perspective into the development of new HIV drugs and the utilization of HIV therapies. See our Statements of beliefs & demands document to see stances on various issues such as inclusion of women in clincal trials, educating clincal trial participants through well-developed informed consents, and studying new antiretroviral treatments on hepatitis C co-infected people prior to a drug's approval.
Co-Chairs:
David Evans
[email protected]
Jeff Taylor
[email protected]
DDC Representative to ATAC Steering Committee:
Michael Dorosh
[email protected]
Join the DDC! To become a DDC member, you must apply to ATAC and be accepted for associate member status. Use the "Membership Application" button to the left to get the process started. Please note: to apply for DDC membership, you will be asked to answer questions related to financial disclosure of any income received from the Pharmaceutical Industry (if any).
If you have any questions, or have problems accessing the online membership application, please contact us:
ATAC
611 Broadway, Suite 613
New York, NY 10012
PHONE: 617.267.0998 E-MAIL: [email protected]
NEW/NOTEWORTHY
Under revision.
REFERENCE MATERIALS
Chart of Drugs in Development
General Resources on Antiretroviral Drugs
Glossaries
DDC Letterhead
BASIC INFORMATION ON PHARMACEUTICAL COMPANIES
There is a web page for each company. Follow the links below. (Note: if there is no link, the company page has not yet been set up.)
Abbott Laboratories (ritonavir, lopinavir/ritonavir)
Agouron/Pfizer Pharmaceuticals (delavirdine, capravirine*, nelfinavir, CCR5 antagonist*)
Boehringer Ingelheim (nevirapine, tipranavir*)
Bristol-Myers Squibb (ddI, d4T, efavirenz, atazanavir, entry/adhesion inhibitor*)
Chiron Corporation (interleukin-2)
Gilead Sciences (tenofovir, emtricitabine)
GlaxoSmithKline (AZT, 3TC, abacavir, amprenavir, fosamprenavir, entry inhibitors*, CCR5 anatgonist*, integrase inhibitor*)
Merck & Co. (indinavir, vaccines*, integrase inhibitor*)
Roche (ddC, saquinavir, enfuvirtide, pegylated interferon for Hep C)
Serono (Human Growth Hormone)
Schering-Plough (Schering C and D fusion inhibitors*, pegylated interferon for Hep C)
Tibotec (TMC125*, TMC114*; genotypic and phenotypic testing; drug level testing)
*under investigation
Reference Materials:
A. General Resources on Antiretroviral Drugs
- Drugs in Development. Source: Rob Camp, Treatment Action Group.
- New Mexico AIDS InfoNet fact sheet #402, Antiviral Drug Names. Includes HIV drugs approved or in clinical trials. Listed by class with generic name, trade name, other names, and manufacturer.
B. Glossaries
Acronyms
AmfAR Treatment Directory Glossary
http://www.amfar.org/cgi-bin/iowa/bridge.html?table=AMFAR_GLOSSARY
CPCRA Glossary of Medical, Statistical, and Clinical Trials Terminology
http://sdmc.cpcra.org/gloss.html
HIV/AIDS Medical Glossary from Gay Men's Health Crisis
http://www.gmhc.org/living/treatment/glossary.html
San Francisco AIDS Foundation Glossary of HIV/AIDS Related Terms
http://www.sfaf.org/treatment/glossary/
HIV Therapeutic Development. An issue of "Research Initiative/Treatment Action!" (RITA!), published by The Center for AIDS: Hope & Remembrance Project.
Drugs in Development
(Source: Rob Camp, Treatment Action Group)
http://www.aidsinfonyc.org/tag/tx/pipeline2006b.html. |